Parametric Portfolio Associates LLC lowered its position in Tocagen Inc (NASDAQ:TOCA) by 73.5% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 35,800 shares of the company’s stock after selling 99,156 shares during the quarter. Parametric Portfolio Associates LLC owned 0.15% of Tocagen worth $44,000 at the end of the most recent quarter.
Separately, Goldman Sachs Group Inc. lifted its holdings in Tocagen by 112.2% in the 4th quarter. Goldman Sachs Group Inc. now owns 48,947 shares of the company’s stock worth $26,000 after buying an additional 25,880 shares in the last quarter. 21.42% of the stock is currently owned by institutional investors and hedge funds.
Separately, Zacks Investment Research lowered shares of Tocagen from a “buy” rating to a “hold” rating in a report on Wednesday, June 10th. Eight analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $1.71.
Shares of Tocagen stock opened at $14.87 on Wednesday. The firm has a market cap of $355.68 million, a PE ratio of -6.27 and a beta of 0.01. The firm’s 50-day simple moving average is $5.09 and its 200-day simple moving average is $2.07. The company has a debt-to-equity ratio of 1.88, a quick ratio of 1.15 and a current ratio of 1.15. Tocagen Inc has a 1 year low of $0.42 and a 1 year high of $6.77.
Tocagen (NASDAQ:TOCA) last issued its earnings results on Thursday, April 23rd. The company reported ($0.43) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.01. Tocagen had a negative net margin of 176,433.34% and a negative return on equity of 327.74%. On average, equities analysts predict that Tocagen Inc will post -2.65 earnings per share for the current year.
Tocagen Inc, a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells.
Further Reading: What is a stock split?
Want to see what other hedge funds are holding TOCA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tocagen Inc (NASDAQ:TOCA).
Receive News & Ratings for Tocagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen and related companies with MarketBeat.com's FREE daily email newsletter.